Terence Fullerton

723 total citations
39 papers, 533 citations indexed

About

Terence Fullerton is a scholar working on Psychiatry and Mental health, Physiology and Pharmacology. According to data from OpenAlex, Terence Fullerton has authored 39 papers receiving a total of 533 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Psychiatry and Mental health, 12 papers in Physiology and 8 papers in Pharmacology. Recurrent topics in Terence Fullerton's work include Migraine and Headache Studies (15 papers), Alzheimer's disease research and treatments (6 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Terence Fullerton is often cited by papers focused on Migraine and Headache Studies (15 papers), Alzheimer's disease research and treatments (6 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Terence Fullerton collaborates with scholars based in United States, United Kingdom and Japan. Terence Fullerton's co-authors include Kaori Ito, Jonathan French, Brian Corrigan, Sima Ahadieh, Thomas G. Tensfeldt, Aaron H. Burstein, Qinying Zhao, Hélène M. Faessel, David J. Clark and Raymond Miller and has published in prestigious journals such as Neurology, Child Development and Clinical Pharmacology & Therapeutics.

In The Last Decade

Terence Fullerton

34 papers receiving 516 citations

Peers

Countries citing papers authored by Terence Fullerton

Since Specialization

Citations

This map shows the geographic impact of Terence Fullerton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terence Fullerton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terence Fullerton more than expected).

Fields of papers citing papers by Terence Fullerton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terence Fullerton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terence Fullerton. The network helps show where Terence Fullerton may publish in the future.

Co-authorship network of co-authors of Terence Fullerton

This figure shows the co-authorship network connecting the top 25 collaborators of Terence Fullerton. A scholar is included among the top collaborators of Terence Fullerton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terence Fullerton. Terence Fullerton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial 2025 ·Headache The Journal of Head and Face Pain ·(unknown), Yasuhiko Matsumori, (unknown), Tomofumi Ishikawa, (unknown), Hiroki‎ Yoshimatsu, Alexandra Thiry, (unknown), Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima	3
2	Plain Language Summary Publication: Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial 2025 ·Headache The Journal of Head and Face Pain ·(unknown), Yasuhiko Matsumori, (unknown), Tomofumi Ishikawa, (unknown), Hiroki‎ Yoshimatsu, Alexandra Thiry, (unknown), Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima	0
3	Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial 2025 ·Headache The Journal of Head and Face Pain ·Koichi Ikeda, Yasuhiko Matsumori, Masako Kudo, Tomofumi Ishikawa, Yuko Hoshino, Hiroki‎ Yoshimatsu, Alexandra Thiry, (unknown), Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima	2
4	A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications 2025 ·Cephalalgia ·Patricia Pozo‐Rosich, (unknown), Paweł Lisewski, Abdullah Nabi Aslan, (unknown), Alexandra Thiry, Lucy Abraham, Luz M. Ramirez, Robert J. Fountaine, Terence Fullerton	0
5	Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial 2025 ·Cephalalgia ·Messoud Ashina, Peter McAllister, Charly Gaul, (unknown), Luz M. Ramirez, (unknown), Alexandra Thiry, Lucy Abraham, Robert J. Fountaine, Terence Fullerton	0
6	A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine 2025 ·Cephalalgia ·Taoufik Alsaadi, (unknown), (unknown), Esha Agarwal, Terence Fullerton, Denise E. Chou, Ed Whalen, (unknown), (unknown), (unknown), (unknown), (unknown), Lucy Abraham, (unknown), (unknown), (unknown), Mohamed I. Hegab, (unknown)	0
7	Rimegepant safety and patient-reported outcomes among triptan-naïve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study 2025 ·Cephalalgia ·Jessica Ailani, Jelena Pavlović, Glenn C. Pixton, Terence Fullerton	1
8	A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention 2025 ·The Journal of Headache and Pain ·Jeremias Antinew, Robert J. Fountaine, (unknown), (unknown), (unknown), (unknown), (unknown), Terence Fullerton	0
9	Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study 2024 ·Cephalalgia ·Kathleen Mullin, Robert Croop, (unknown), Terence Fullerton, Jennifer Madonia, Richard B. Lipton	5
10	Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study 2024 ·Pain and Therapy ·David Kudrow, Susan Hutchinson, Glenn C. Pixton, Terence Fullerton	1
11	Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics 2024 ·Journal of Pain Research ·Terence Fullerton, Glenn C. Pixton	8
12	A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil 2018 ·Alzheimer s Research & Therapy ·Terence Fullerton, Brendon Binneman, William David, Marielle Delnomdedieu, James W. Kupiec, Peter Lockwood, Jessica Mancuso, Jeffrey Miceli, J. Simon Bell	27
13	Pharmacokinetics, Safety, and Tolerability Following Multiple Oral Doses of Varenicline Under Various Titration Schedules in Elderly Nonsmokers 2010 ·The Journal of Clinical Pharmacology ·Qinying Zhao, Elias Schwam, Terence Fullerton, Melissa O’Gorman, Aaron H. Burstein	8
14	Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe 2009 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown), Nervin Lawendy, Terence Fullerton, Peter J. Snyder, Anne N. Nafziger, Joseph Bertino	16
15	Pharmacokinetics, Safety, and Tolerability After Single and Multiple Oral Doses of Varenicline in Elderly Smokers 2006 ·The Journal of Clinical Pharmacology ·Aaron H. Burstein, Terence Fullerton, David J. Clark, Hélène M. Faessel	44
16	The Pharmacodynamics of Sumatriptan in Nitroglycerin‐Induced Headache 1999 ·The Journal of Clinical Pharmacology ·Terence Fullerton, (unknown), Alan Forrest, Fran M. Gengo	21
17	Oculogyric Crisis Possibly Related to Pentazocine 1993 ·Annals of Pharmacotherapy ·Aaron H. Burstein, Terence Fullerton	9
18	Evaluation of the Renal Protective Effect of Misoprostol in Elderly, Osteoarthritic Patients at Risk for Nonsteroidal Anti‐inflammatory Drug‐Induced Renal Dysfunction 1993 ·The Journal of Clinical Pharmacology ·Terence Fullerton, Domenic A. Sica, Robert A. Blum	8
19	Sumatriptan: A Selective 5-Hydroxytryptamine Receptor Agonist for the Acute Treatment of Migraine 1992 ·Annals of Pharmacotherapy ·Terence Fullerton, Fran M. Gengo	11
20	Prolonged Nausea and Vomiting Associated with Buprenorphine 1991 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Terence Fullerton, (unknown), (unknown), Joseph Bertino	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact